Andy I Chen
Overview
Explore the profile of Andy I Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1111
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Riedell P, Grady C, Nastoupil L, Luna A, Luna de Abia A, Ahmed N, et al.
Blood Adv
. 2024 Dec;
9(5):1232-1241.
PMID: 39657136
Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed chimeric antigen receptor T-cell therapy approved for the treatment of relapsed/refractory large B-cell lymphoma. We present a multicenter retrospective study evaluating safety, efficacy,...
2.
Ahmed N, Wesson W, Lutfi F, Porter D, Bachanova V, Nastoupil L, et al.
Blood Adv
. 2024 Jul;
8(20):5346-5354.
PMID: 39042880
CD19-directed chimeric antigen receptor T-cell (CAR T) therapies, including axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel), have transformed the treatment landscape for B-cell non-Hodgkin lymphoma, showcasing significant efficacy...
3.
Epperla N, Hashmi H, Ahn K, Allbee-Johnson M, Chen A, Wirk B, et al.
Br J Haematol
. 2024 May;
205(3):1202-1207.
PMID: 38797526
No abstract available.
4.
Ghilardi G, Williamson S, Pajarillo R, Paruzzo L, Chen L, Grady C, et al.
NEJM Evid
. 2024 May;
3(4):EVIDoa2300213.
PMID: 38776868
Background: Administration of anti-CD19 chimeric antigen receptor T-cell (CART19) immunotherapy for large B-cell lymphomas (LBCLs), a subset of non-Hodgkin lymphoma (NHL), involves high costs and access to specialized tertiary care...
5.
Dreyling M, Fowler N, Dickinson M, Martinez-Lopez J, Kolstad A, Butler J, et al.
Blood
. 2024 Jan;
143(17):1713-1725.
PMID: 38194692
Tisagenlecleucel is approved for adults with relapsed/refractory (r/r) follicular lymphoma (FL) in the third- or later-line setting. The primary analysis (median follow-up, 17 months) of the phase 2 ELARA trial...
6.
7.
Galligan D, Williamson S, Myers J, Chen A, Hayes-Lattin B, Okada C, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Sep;
23(12):874-881.
PMID: 37741763
Background: Peripheral T-cell lymphomas (PTCL) are a group of aggressive malignancies with inferior outcomes compared to B-cell non-Hodgkin lymphoma (NHL). Both allogeneic and autologous hematopoietic cell transplantation (HCT) are commonly...
8.
Scordo M, Flynn J, Gonen M, Devlin S, Parascondola A, Tomas A, et al.
Blood Adv
. 2023 Jul;
7(18):5579-5585.
PMID: 37522731
Fludarabine is one of the most common agents given for lymphodepletion before CD19 chimeric antigen receptor T cells, but its optimal therapeutic intensity is unknown. Using data from a multicenter...
9.
Bubalo J, Radke J, Bensch K, Chen A, Misra S, Maziarz R
J Oncol Pharm Pract
. 2023 May;
30(2):304-312.
PMID: 37151021
The purpose of this study was to investigate the efficacy and safety of netupitant/palonosetron (NEPA) for the prevention of chemotherapy-induced nausea and vomiting (CINV) for hematopoietic cell transplantation (HCT) patients...
10.
Bhaskar S, Patel V, Porter D, Schuster S, Nastoupil L, Perales M, et al.
Blood Adv
. 2022 Dec;
7(17):4765-4772.
PMID: 36508286
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of many patients with aggressive relapsed or refractory large B-cell lymphoma (LBCL). Treatment can be complicated by clinically evident cytokine...